SS Innovations International (SSII) Earnings Date & Reports

Key Takeaways

• SS Innovations International is expected to report its third-quarter 2026 results in early November, with analysts modeling revenue of roughly $15.1 million.
• Consensus estimates call for a net loss of about $0.01 per share, roughly in line with the prior quarter's results.
• Investor attention is likely to center on SSi Mantra installations, procedure volumes, and updates on the company's U.S. Food and Drug Administration (FDA) 510(k) submission.
• The company has delivered strong year-over-year revenue growth, but continues to operate at a net loss as it scales its surgical robotics platform.
• In its most recent quarter, revenue of $13.94 million came in roughly 16% above consensus, while earnings per share matched expectations.
• For more context on this ticker, explore its Major News, Today's Price Move, Price Targets, and Forecast pages.
• You can also discover automated trading ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

SS Innovations International (SSII) is a commercial-stage surgical robotics company whose flagship SSi Mantra system competes in a fast-growing but capital-intensive medical technology market. The third-quarter report matters because it offers a fresh read on whether the company can sustain its rapid revenue expansion while managing losses tied to commercialization, regulatory work, and geographic expansion. After reporting a record quarter in Q2 2026, investors will be watching whether momentum in India and other international markets carries forward. The print also arrives as the company works through its FDA 510(k) submission process, a potential catalyst that could open the door to the larger U.S. market.

Earnings Expectations

For the third quarter of 2026, analyst consensus points to revenue of approximately $15.1 million and a net loss of about $0.01 per share. That revenue estimate implies a meaningful increase from the $12.83 million reported in the year-ago quarter. For comparison, the company's Q2 2026 results delivered revenue of $13.94 million, beating the roughly $12 million consensus estimate by about 16%, while earnings per share of -$0.01 matched expectations. In Q1 2026, revenue came in at about $11.1 million, up more than 100% year over year. Because the company is not yet profitable, investors are likely to focus less on the bottom line and more on top-line growth, gross margin trends, installation counts, and any commentary on regulatory milestones.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a useful complement to traditional research around events like quarterly earnings reports.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter report is shaped by a sharp decline in the share price over the past year, alongside continued optimism around the company's longer-term growth story. The stock has pulled back considerably from its 52-week high, and thin average trading volume can amplify price moves around earnings. Key risk factors include ongoing cash burn, a working capital picture that management has flagged as requiring additional funding, and uncertainty around the timing of regulatory approval in the United States. Positive commentary on SSi Mantra adoption or progress on the FDA submission could support sentiment, while any sign of slowing installations or widening losses may weigh on the stock.

Forward Outlook and Key Factors to Monitor

Beyond the third-quarter headline numbers, investors will want to track several forward-looking signals. First, installation and procedure volume for the SSi Mantra system remain the clearest indicators of commercial traction, particularly in India and other emerging markets where the company has been expanding.

Second, the FDA 510(k) process is a major catalyst. The company recently submitted its response to a request for additional information from the agency, and any update on timing or next steps could meaningfully shape the investment narrative around U.S. market entry.

Third, cost discipline and cash management will stay in focus. The company has raised capital through a private placement, but management has acknowledged that existing resources may not fully fund operations over the next twelve months, so commentary on funding plans and operating expenses will be important.

Finally, gross margin trends and geographic revenue mix will help investors judge whether growth is translating into a more efficient business. While the company continues to invest in regulatory clearance and market development, sustained top-line momentum remains the foundation of the bull case.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations